Discuss new oncology drugs for children at Paediatric Clinical Trials this March

Top Quote "Childhood and adolescent cancers remain a major cause of morbidity, mortality and social concern in Europe with 3000 children and adolescents dying of cancer each year… Fresh approaches to the many complex aspects of treating childhood cancers are urgently needed, including faster introduction of new medicines for children. End Quote
  • (1888PressRelease) March 07, 2016 - SMi Group reports: Sabine Fuerst-Recktenwald, Senior Medical Director Paediatric Oncology, Roche Pharmaceuticals will be presenting on: "Challenges in paediatric drug development: new oncology drugs for children" at the SMi's 10th annual Paediatric Clinical Trials event (16-17 March 2016, London, UK).

    In the run-up to the event, SMi Group has caught up with Sabine to find out her thoughts about the current industry issues. Here is what she thinks is the take home message from her presentation:
    " Children with cancer still do not have timely access to safe and efficacious drugs. Roche has a unique approach to address this challenges via an internal specialized team and a portfolio approach/Matrix trial. Collaboration of all stakeholder (industry, academia, regulators, patients) will be a key".

    Presentation topics will include:
    -The "optimal" timing
    - A more sustainable «Mode of Action» based drug development model
    - Historical adult-centric versus integrated paediatric development at Roche
    - Long-term safety considerations

    Another key presentations will include:
    - Why paediatric formulation development does matter (Co-chair, Philippe Auby, Vice President of Global Clinical Research Paediatric Neuro-Psychiatry, Lundbeck SAS)
    - Challenge of the development of analgesics in paediatric population (Ronald Rosenburg, Senior International Clinical Lead, Grunenthal)
    - Safety considerations of paediatric clinical trial (Robert Kahn, Safety Science Leader, Pediatric Oncology Drug Development, Genencor International)
    - Challenges of drug development in rare diseases-inhalation anthrax (Sangeeta Sedani, Clinical Investigation Lead, GSK)
    - Networking in paediatric oncology (Ellen Bolotin, Global Clinical Leader in Paediatrics, Bayer)

    For more information and full event agenda please visit : www.paediatric-trials.co.uk/1888

    In addition to the conference attendees will have the opportunity to participate in an exclusive full day pre-conference workshop which will be held on the 15th March 2016. The workshop entitled 'Drug development in the paediatric population' will be led by Klaus Rose, CEO, Klausrose Consulting.

    Registration is closing! Those who are interested in attendance are advised to book now at www.paediatric-trials.co.uk/1888

    For sponsorship opportunities contact Alia Malick on +44 (0) 20 7827 6168 or email: amalick ( @ ) smi-online dot co dot uk

    For delegate enquires contact Matthew Apps on +44 (0) 20 7827 6093 or email mapps ( @ ) smi-online dot co dot uk

    About SMi Group:
    Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

  • FB Icon Twitter Icon In-Icon
Contact Information